Low-dose sirolimus combined with angiotensin-converting enzyme inhibitor and statin stabilizes renal function and reduces glomerular proliferation in poor prognosis IgA nephropathy

Nephrology Dialysis Transplantation

Volumn 26, Issue 11, 2011, Pages 3596-3602

  Cruzado, Josep M ^a   Poveda, Rafael ^a   Ibernón, Meritxell ^b   Díaz, Montserrat ^c   Fulladosa, Xavier ^a   Carrera, Marta ^a   Torras, Joan ^a   Bestard, Oriol ^a   Navarro, Itziar ^a   Ballarín, José ^c   Romero, Ramón ^b   Grinyó, Josep M ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c FUNDACIÓ PUIGVERT   (Spain)

Author keywords

angiotensin converting inhibitor; IgA nephropathy; immunosuppression; sirolimus; statin

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; CALCIUM CHANNEL BLOCKING AGENT RECEPTOR; CHOLESTEROL; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; RAPAMYCIN; STEROID; TACROLIMUS;

ACUTE DISEASE; ADULT; AGED; ANEMIA; ARTICLE; BLOOD PRESSURE; CAPILLARY PROLIFERATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE CONTROL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FACE RASH; FEMALE; GASTRITIS; GLOMERULOPATHY; GLOMERULUS FILTRATION RATE; HEMATURIA; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERKALEMIA; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY FUNCTION; LOW DRUG DOSE; MALE; MESANGIUM CELL; PILOT STUDY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE DISEASE; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; CASE-CONTROL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ENALAPRIL; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GLOMERULONEPHRITIS, IGA; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY GLOMERULUS; MALE; MIDDLE AGED; PILOT PROJECTS; PROGNOSIS; PROSPECTIVE STUDIES; PYRROLES; SIROLIMUS; YOUNG ADULT;

EID: 80155192344     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr072     Document Type: Article

References (27)

1. Donadio JV, Grande JP. IgA nephropathy. N Engl J Med 2002; 347: 738-748
2. Rivera F, Lopez-Gomez JM, Perez-Garcia R. Frequency of renal pathology in Spain 1994-1999. Nephrol Dial Transplant 2002; 17: 1594-1602
3. Donadio JV Jr, Grande JP. Immunoglobulin A nephropathy: A clinical perspective. J Am Soc Nephrol 1997; 8: 1324-1332
4. Floege J, Feehally J. IgA nephropathy: Recent developments. J Am Soc Nephrol 2000; 11: 2395-2403
5. Floege J, Eitner F. Combined immunosuppression in high risk patients with IgA nephropathy? J Am Soc Nephrol 2010; 21: 1604-1606
6. Praga M, Gutiérrez E, González E et al. Treatment of IgA nephropathy with ACE inhibitors: A randomized and controlled trial. J Am Soc Nephrol 2003; 14: 1578-1583
7. Buemi M, Allegra A, Corica F et al. Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy. Clin Pharmacol Ther 2000; 67: 427-431
8. Donadio JV Jr, Bergstralh EJ, Offord KP et al. A controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group. N Engl J Med 1994; 331: 1194-1199
9. Pozzi C, Bolasco PG, Fogazzi GB et al. Corticosteroids in IgA nephropathy: A randomised controlled trial. Lancet 1999; 353: 883-887
10. Ballardie FW. Quantitative appraisal of treatment options for IgA nephropathy. J Am Soc Nephrol 2007; 18: 2806-2809
11. Cruzado JM. Nonimmunosuppressive effects of mammalian target of rapamycin inhibitors. Transplant Rev (Orlando) 2008; 22: 73-81
12. Tumlin JA, Miller D, Near M et al. A prospective, open-label trial of sirolimus in the treatment of focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2006; 1: 109-116
13. Fervenza FC, Fitzpatrick PM, Mertz J et al. Acute rapamycin nephrotoxicity in native kidneys of patients with chronic glomerulopathies. Nephrol Dial Transplant 2004; 19: 1288-1292
14. Wang W, Chan YH, Lee W et al. Effect of rapamycin and FK506 on mesangial cell proliferation. Transplant Proc 2001; 33: 1036-1037
15. Lock HR, Sacks SH, Robson MG. Rapamycin at subimmunosuppressive levels inhibits mesangial cell proliferation and extracellular matrix production. Am J Physiol Renal Physiol 2007; 292: F76-F81
16. Krämer S, Wang-Rosenke Y, Scholl V et al. Low-dose mTOR inhibition by rapamycin attenuates progression in anti-thy1-induced chronic glomerulosclerosis of the rat. Am J Physiol Renal Physiol 2008; 294: F440-F449
17. Cattran DC, Coppo R, Cook HT et al. The Oxford classification of IgA nephropathy: Rationale, clinicopathological correlations, and classification. Kidney Int 2009; 76: 534-545
18. Syrjänen J, Mustonen J, Pasternack A. Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy. Nephrol Dial Transplant 2000; 15: 34-42
19. Lloberas N, Cruzado JM, Franquesa M et al. Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats. J Am Soc Nephrol 2006; 17: 1395-1404
20. Torras J, Herrero-Fresneda I, Gulias et al. Rapamycin has dual opposing effects on proteinuric experimental nephropathies: Is it a matter of podocyte damage? Nephrol Dial Transplant 2009; 24: 3632-3640
21. Grinyó JM, Cruzado JM. Mycophenolate mofetil and sirolimus combination in renal transplantation. Am J Transplant 2006; 6: 1991-1999
22. Padiyar A, Bodziak KA, Hricik DE et al. Clinical predictors of proteinuria after conversion to sirolimus in kidney transplant recipients. Am J Transplant 2010; 10: 310-314
23. Biancone L, Bussolati B, Mazzucco G et al. Loss of nephrin expression in glomeruli of kidney-transplanted patients under m-TOR inhibitor therapy. Am J Transplant 2010; 10: 2270-2278
24. Letavernier E, Bruneval P, Vandermeersch S et al. Sirolimus interacts with pathways essential for podocyte integrity. Nephrol Dial Transplant 2009; 24: 630-638
25. Lieberthal W, Levine JS. The role of the mammalian target of rapamycin (mTOR) in renal disease. J Am Soc Nephrol 2009; 20: 2493-2502
26. Poon M, Marx SO, Gallo R et al. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest 1996; 98: 2277-2283
27. Taguma Y, Kitamoto Y, Futaki G et al. Effect of captopril on heavy proteinuria in azotemic diabetics. N Engl J Med 1985; 313: 1617-1620